Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Erin Medoff"'
Autor:
Kathryn Pratt, Stuart Seropian, Iris Isufi, Sarah Perreault, Francine M. Foss, Erin Medoff, Dennis L. Cooper, Julie Baker
Publikováno v:
Supportive Care in Cancer. 25:205-208
Purpose Carmustine (BCNU) is used in the conditioning regimens BEAM and CBV for autologous stem cell transplantation. Carmustine-related infusion reactions, while not described in the BEAM literature, occurred in 95 % of patients who received CBV. Th
Autor:
Kathryn Pratt, Erin Medoff, Sarah Perreault, Yanyun Wu, Dennis L. Cooper, Julie Baker, Stuart Seropian, Francine M. Foss, Natalie Patel
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 16:411-416
Background Autologous stem cell transplantation remains important in the treatment of myeloma and relapsed lymphoma. Plerixafor has been shown to significantly enhance stem cell mobilization but is very expensive. Patients and Methods We evaluated pl
Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies
Autor:
Erin Medoff, Mina L. Xu, Anna Folkers, Susanna A Curtis, Amer M. Zeidan, Rory M. Shallis, Rose Mixon
Publikováno v:
Annals of hematology. 97(11)
Autor:
Stacy Stickney Ferguson, Erin Medoff, Deborah Yolin Raley, Ellen M. Denzen, Jeffrey Chell, Helen Leather, Michael Lill, Richard E. Champlin, Kim Schmit-Pokorny, Linda J. Burns, Elizabeth Murphy, Arthur W. Bracey, Laura Wiggins, Richard T. Maziarz, Edward L. Snyder, Joyce Neumann, Claudio Anasetti, Navneet S. Majhail
Publikováno v:
Biology of Blood and Marrow Transplantation. 19:4-11
The National Marrow Donor Program, in partnership with the American Society for Blood and Marrow Transplantation, sponsored and organized a series of symposia to identify complex issues affecting the delivery of hematopoietic cell transplantation (HC
Autor:
Erin Medoff, Yanyun Wu, Diane S. Krause, Stuart Seropian, Edward L. Snyder, Maria Proytcheva, Dennis L. Cooper
Publikováno v:
Journal of Clinical Apheresis. 27:235-241
Background: Granulocyte Colony-Stimulating Factor (G-CSF) alone or in conjunction with chemotherapy is commonly used to mobilize hematopoietic progenitor cells (HPC) into peripheral blood for progenitor cell harvest for autologous HPC transplantation
Autor:
Erin Medoff, Arthur W. Bracey, Richard E. Champlin, Navneet S. Majhail, Elizabeth Murphy, Ellen M. Denzen, Richard T. Maziarz, Edward L. Snyder, Stacy Stickney Ferguson, Linda J. Burns, Miriam Markowitz, Joyce Neumann, Claudio Anasetti, Daniel J. Weisdorf, Deborah Yolin Raley, Norman Hubbard, Jeffrey Chell, Kim Schmit-Pokorny
Publikováno v:
Biology of Blood and Marrow Transplantation. 18(2):172-182
Hematopoietic cell transplantation (HCT) is the only known curative therapy for many patients with life-threatening hematologic and oncologic diseases. It is estimated that the National Marrow Donor Program(®) (NMDP) will facilitate 10,000 transplan
Publikováno v:
Transfusion. 47:115-119
BACKGROUND: The brief period of neutropenia and limited nonmarrow toxicity after high-dose melphalan (HDM) provide a rationale for outpatient treatment. STUDY DESIGN AND METHODS: Our experience with HDM (140-200 mg/m2) in 90 consecutive transplant ep
Autor:
Erin Medoff, Sarah Perreault, Julie Baker, Kathryn Pratt, Stuart Seropian, Francine M. Foss, Dennis L. Cooper, Iris Isufi
Publikováno v:
Biology of Blood and Marrow Transplantation. 22:S130-S131
Autor:
Carol Staugaard-Hahn, Elizabeth D'Andrea, Bruce G. Haffty, Barbara Burtness, Michal G. Rose, Josette Bou-Khalil, Edward A. Snyder, Dennis L. Cooper, John Pezzimente, Michael Reiss, Susan Gran, Erin Medoff, Christine Holtkamp, Amanda Psyrri
Publikováno v:
The Breast Journal. 9:472-477
Patients who receive neoadjuvant chemotherapy for locally advanced breast cancer and have four or more ipsilateral axillary lymph nodes involved at surgery are at high risk for recurrence, with a median time to relapse of 18 months. We offered such p
Autor:
Stuart Seropian, Erin Medoff, Francine M. Foss, Wu Yen, Edward L. Snyder, Ann Conkling-Walsh, Julie Baker, Dennis L. Cooper, Kathryn Pratt
Publikováno v:
Clinical lymphoma, myelomaleukemia. 11(3)
Plerixafor was recently approved for stem cell mobilization in patients who have non-Hodgkin lymphoma or multiple myeloma. However, the use of late evening (10 PM) injections is inconvenient for patients and requires an after-hours infrastructure tha